iRadimed(US:IRMD)2026-02-10 13:00Financial Performance - The Company reported record revenue of $22.7 million for Q4 2025, a 17% increase year-over-year, exceeding previous guidance [3] - For the full year 2025, the Company reported revenue of $83.8 million, a 14% increase from $73.2 million in 2024 [11] - Revenue for Q4 2025 reached $22.692 million, a 17.8% increase from $19.389 million in Q4 2024 [37] - Gross profit for the year ended December 31, 2025, was $64.324 million, up 14.1% from $56.350 million in 2024 [37] - Operating expenses for the year ended December 31, 2025, totaled $38.177 million, a 10.4% increase from $34.385 million in 2024 [37] Earnings - GAAP diluted EPS for Q4 2025 was $0.50, a 25% increase compared to Q4 2024, while non-GAAP diluted EPS was $0.54, a 23% increase [8] - Net income for Q4 2025 was $6.442 million, representing a 25.1% increase compared to $5.147 million in Q4 2024 [37] - Non-GAAP net income for Q4 2025 was $7.0 million, a 23% increase from $5.7 million in Q4 2024 [10] - Non-GAAP net income for the year ended December 31, 2025, was $24.792 million, a 16.5% increase from $21.228 million in 2024 [39] - The company reported a diluted net income per share of $0.50 for Q4 2025, compared to $0.40 for Q4 2024, marking a 25% increase [37] Cash Flow and Dividends - Cash flow from operations for Q4 2025 was $5.9 million, a slight decrease of 2% from $6.0 million in Q4 2024 [15] - Free cash flow for Q4 2025 was $5.506 million, significantly up from $2.930 million in Q4 2024 [41] - The Company declared a regular quarterly cash dividend of $0.20 per share, up from $0.17 per share, reflecting confidence in the business outlook [4] Guidance and Future Outlook - For full year 2026 guidance, the Company expects revenue between $91.0 million and $96.0 million, with GAAP diluted EPS between $1.90 and $2.05 [5] - The company anticipates meaningful revenue contributions from the next-generation 3870 MRI-compatible IV infusion pump in the future [31] Sales and Market Performance - Domestic sales accounted for 81% of total revenue in Q4 2025, down from 85% in 2024, while gross profit margin was 75% [13] - The Company shipped 3,870 units of the next-generation 3870 MRI-compatible IV infusion pump in Q4 2025, with full rollout expected in Q1 2026 [3] Assets and Equity - Total assets increased to $108.776 million in 2025, compared to $98.326 million in 2024, reflecting a growth of 10.8% [35] - Total stockholders' equity rose to $94.618 million in 2025, up from $86.819 million in 2024, indicating an increase of 9.9% [35] Stock-Based Compensation - The Company expects stock-based compensation expense to be approximately $2.0 million for the full year 2026 [18]